BXMPY (Beximco Pharmaceuticals) EPS (Diluted): $0.16 (TTM As of Mar. 2026)


What is Beximco Pharmaceuticals EPS (Diluted)?

Beximco Pharmaceuticals BXMPY 93 EPS (Diluted) is $0.16 as of Mar. 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 4 warning signs investors should review.

Beximco Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.16.

Beximco Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was $0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.16.

Beximco Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was $0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.16.

During the past 12 months, Beximco Pharmaceuticals's average EPS without NRIGrowth Rate was 28.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 10.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Beximco Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 27.40% per year. The lowest was -14.50% per year. And the median was 13.70% per year.

Beximco Pharmaceuticals  (OTCPK:BXMPY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Beximco Pharmaceuticals EPS (Diluted) Related Terms

Beximco Pharmaceuticals EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals EPS (Diluted) Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.09 0.08 0.11 0.13

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.04 0.04 0.04

BXMPY vs ZTS, UTHR: EPS (Diluted) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beximco Pharmaceuticals PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's PE Ratio falls into.


Beximco Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Beximco Pharmaceuticals's Diluted EPS for the fiscal year that ended in Jun. 2025 is calculated as

Diluted EPS (A: Jun. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(56.274-0)/446.112
=0.13

Beximco Pharmaceuticals's Diluted EPS for the quarter that ended in Mar. 2026 is calculated as

Diluted EPS (Q: Mar. 2026 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(17.999-0)/446.112
=0.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of $0.16 mean?
Beximco Pharmaceuticals (BXMPY) has a EPS (Diluted) of $0.16 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' EPS (Diluted) too high?
Beximco Pharmaceuticals' current EPS (Diluted) is $0.16. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' EPS (Diluted) compare to ZTS and UTHR?
Beximco Pharmaceuticals' EPS (Diluted) of $0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current EPS (Diluted) is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current EPS (Diluted) of $0.16. The current EPS (Diluted) is $0.16. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current EPS (Diluted) is $0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.